Home›Liraglutide

Liraglutide

Also known as: Liraglutide

GLP-1 Receptor AgonistGlucagon-like Peptide-1 (GLP-1) Agonists

Route: Subcutaneous

7 interactions on record⛔ Black Box Warning

Liraglutide has 7 known drug interactions based on U.S. FDA drug labeling data. 4 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Insulin Degludec, Insulin Glargine-Yfgn, Insulin Human. Patients taking Liraglutide should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 7
Major: 4
Moderate: 3

Major (4)

Liraglutide + Insulin Degludec— May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.
Liraglutide + Insulin Glargine-Yfgn— May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.
Liraglutide + Insulin Human— Liraglutide stimulates insulin release and increases risk of hypoglycemia, including severe hypoglycemia, when combined …
Liraglutide + Sulfonylurea— Liraglutide stimulates insulin release and increases risk of hypoglycemia, including severe hypoglycemia, when combined …

Moderate (3)

Liraglutide + Insulin Detemir— May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.
Liraglutide + Insulin Glargine— May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.
Liraglutide + Insulin Glargine-Aglr— May increase risk of hypoglycemia. Dosage reductions and increased frequency of glucose monitoring may be required.

Liraglutide + Insulin Degludec⚠️Major

May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.

Liraglutide + Insulin Glargine-Yfgn⚠️Major

May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.

Liraglutide + Insulin Human⚠️Major

Liraglutide stimulates insulin release and increases risk of hypoglycemia, including severe hypoglycemia, when combined with insulin. Consider reducing insulin dose.

Liraglutide + Sulfonylurea⚠️Major

Liraglutide stimulates insulin release and increases risk of hypoglycemia, including severe hypoglycemia, when combined with sulfonylureas. Consider reducing sulfonylurea dose.

Liraglutide + Insulin Detemir🟡Moderate

May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.

Liraglutide + Insulin Glargine🟡Moderate

May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.

Liraglutide + Insulin Glargine-Aglr🟡Moderate

May increase risk of hypoglycemia. Dosage reductions and increased frequency of glucose monitoring may be required.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.